Back to results
US 2006/0040858 A1Published application
Novel peptides that bind to the erythropoietin receptor
AssigneeAffymax, Inc.
InventorsChristopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Claims1
A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises a peptide dimer having the formula:
- wherein
- (i) in each peptide monomer of the peptide dimer, each amino acid is indicated by standard one letter abbreviation, AcG is N-acetylglycine, and 1-nal is 1-naphthylalanine;
- (ii) each peptide monomer of the peptide dimer contains an intramolecular disulfide bond between the two cysteine (C) residues of each monomer
- (iii) [“PEG”] comprises at least one linear polyethylene glycol (PEG) moiety, each PEG moiety having a molecular weight of about 20,000 to about 40,000 Daltons.
1 more element
Dependencies are inferred from the claim text.